These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7543010)

  • 1. Schedule-intensified M-VAC chemotherapy for advanced urothelial cancer with recombinant human granulocyte colony stimulating factor (rhG-CSF).
    Noguchi S; Kubota Y; Shuin T; Hosaka M; Miura T; Kondoh I
    Int J Urol; 1994 Jun; 1(2):140-2. PubMed ID: 7543010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
    Noguchi S; Kubota Y; Shuin T; Masuda M; Misaki H; Yao M; Kondoh K; Sakuramoto T; Hosaka M
    Hinyokika Kiyo; 1994 Aug; 40(8):677-82. PubMed ID: 7942364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
    J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer.
    Miyanaga N; Akaza H; Shimazui T; Ohtani M; Koiso K
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S5-8. PubMed ID: 7527735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.
    Seidman AD; Scher HI; Gabrilove JL; Bajorin DF; Motzer RJ; O'Dell M; Curley T; Dershaw DD; Quinlivan S; Tao Y
    J Clin Oncol; 1993 Mar; 11(3):408-14. PubMed ID: 7680373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
    J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group.
    Kuroda M; Kotake T; Akaza H; Hinotsu S; Kakizoe T
    Jpn J Clin Oncol; 1998 Aug; 28(8):497-501. PubMed ID: 9769784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors.
    Sternberg CN; de Mulder PH; van Oosterom AT; Fossa SD; Giannarelli D; Soedirman JR
    Ann Oncol; 1993 May; 4(5):403-7. PubMed ID: 8353075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. A randomized study.
    Pizzocaro G; Milani A; Piva L; Faustini M; Spino E
    Eur Urol; 1991; 20(2):89-92. PubMed ID: 1752280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
    Nakanishi S; Matsuzaki M; Morikawa H; Nakano M; Komatsu H
    Hinyokika Kiyo; 2004 Oct; 50(10):667-71. PubMed ID: 15575216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity].
    Igawa M; Kadena H; Ohkuchi T; Ueda M; Usui T
    Nihon Hinyokika Gakkai Zasshi; 1991 Oct; 82(10):1627-36. PubMed ID: 1770701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.
    Moore MJ; Iscoe N; Tannock IF
    J Urol; 1993 Oct; 150(4):1131-4. PubMed ID: 8371371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity.
    Conti JA; Scher HI
    Cancer; 1992 Dec; 70(11):2699-702. PubMed ID: 1384952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin) with granulocyte colony-stimulating factor for the treatment of urothelial cancer: an effective and safe chemotherapy regimen.
    Igawa M; Kadena H; Ueda M; Usui T
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S1-4. PubMed ID: 7527732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of recombinant human granulocyte colony-stimulating factor in patients receiving chemotherapy for urogenital cancer. Urological rhG-CSF Study Group.
    Aso Y; Akaza H
    J Urol; 1992 Apr; 147(4):1060-4. PubMed ID: 1372661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
    Viens P; Gravis G; Bladou F; Lechevallier E; Baume D; Camerlo J; Cowen D; Coulange C; Serment G; Resbeut M; Maraninchi D
    Eur Cytokine Netw; 1996 Sep; 7(3):395-9. PubMed ID: 8954183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination chemotherapy of advanced urothelial cancer with methotrexate, vinblastine, adriamycin and cisplatin (M-VAC)].
    Nakagawa S; Nakao M; Toyoda K; Nukui M; Takada H; Ebisui K; Watanabe H; Kobayashi T; Maegawa M
    Nihon Hinyokika Gakkai Zasshi; 1988 Sep; 79(9):1510-5. PubMed ID: 3244217
    [No Abstract]   [Full Text] [Related]  

  • 18. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
    Narita S; Nakano M; Matsuzaki M; Watanabe J; Morikawa H; Murata H; Oda H; Komatsu H
    Hinyokika Kiyo; 2005 Mar; 51(3):155-8. PubMed ID: 15852667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
    Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T
    Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium.
    Gabrilove JL; Jakubowski A; Scher H; Sternberg C; Wong G; Grous J; Yagoda A; Fain K; Moore MA; Clarkson B; Oettgen HF; Alton K; Welte K; Souza L
    N Engl J Med; 1988 Jun; 318(22):1414-22. PubMed ID: 2452983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.